Table: Astellas -Q1 group results (IFRS)

Astellas Pharma

05/08/2026 07:31

   Aug 5 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2026        Jun 30, 2025     Mar 31, 2027 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              640.91              505.79          2.22 trln  
                   (+26.7 pct)         (+6.9 pct)       (+3.8 pct)  
  Operating          184.51               94.65           395.00    
                   (+94.9 pct)         (+86.8 pct)      (+3.2 pct)  
  Pretax             186.51               90.42           385.00    
                  (+106.3 pct)         (+79.1 pct)      (+2.2 pct)  
  Net                141.83               68.42           300.00    
                  (+107.3 pct)         (+82.0 pct)      (+2.9 pct)  
  EPS Basic         79.15 yen           38.22 yen       167.46 yen  
  EPS Diluted       78.96 yen           38.11 yen                   
  Ann Div                               78.00 yen        80.00 yen  
  -Q2 Div                               39.00 yen        40.00 yen  
  -Q4 Div                               39.00 yen        40.00 yen  
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T